Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis
Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that can lead to end-stage renal disease and death. The aim of this study was to compare the efficacy and safety of mycophenolate mofetil (MMF) and cyclophosphamide as induction therapy and subsequently as maintenan...
Gespeichert in:
| Veröffentlicht in: | Iranian journal of kidney diseases 2018-09, Vol.12 (5), p.288 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 288 |
| container_title | Iranian journal of kidney diseases |
| container_volume | 12 |
| creator | Gadakchi, Leyla Hajialilo, Mehrzad Nakhjavani, Mohammad-Reza Abedi Azar, Sima Kolahi, Sousan Gojazadeh, Morteza Ebrahimi, Ali-Asghar Malek Mahdavi, Aida Noshad, Hamid Khabbazi, Alireza |
| description | Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that can lead to end-stage renal disease and death. The aim of this study was to compare the efficacy and safety of mycophenolate mofetil (MMF) and cyclophosphamide as induction therapy and subsequently as maintenance therapy for lupus nephritis.
In this retrospective case-control study, 67 patients with proliferative lupus nephritis who were treated with MMF (n = 45) and pulse of intravenous cyclophosphamide (n = 22) were included. Remission of the kidney disease, mortality, and adverse events were evaluated and compared between the two groups.
The 45 patients treated with MMF had a mean age of 33.8 ± 10.6 years and 17.1% of them were males. The 22 patients treated with pulse of intravenous cyclophosphamide had a mean age of 38.1 ± 11.1 years and 18.2% of them were males. Complete and partial kidney remission occurred in 40% and 42.2% of the patients treated with MMF and in 31.8% and 59.1% of the patients treated with cyclophosphamide, respectively. No significant differences were observed in complete and partial remission between the two groups. No mortality was reported in the studied patients. There were no significant differences in the frequency of adverse events between the two groups.
The efficacy of MMF in long-term treatment of lupus nephritis was comparable to that of cyclophosphamide, and there is no significant differences in the rate of side effects between the two regimens. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2352716691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352716691</sourcerecordid><originalsourceid>FETCH-LOGICAL-p206t-9faec6b448a97a235d57e2684584ed6d6c1100601035d550fcb7a1e1bb84bc663</originalsourceid><addsrcrecordid>eNo1kN9KwzAUxoMobk5fQQJeF5L-SdtLGVMHmw6c3pY0PaEZbROTdNB38KHNcLs63znfx-9wzhWa0zzJooKR9PqisyKeoTvnDoSwpEzJLZolJGE5ickc_a6kVIKLCfOhwZ9cgp-wlng7CW1aGHTHPeCtDnPV4W-wbnR4PXjLj8EMejd2DvByEl3Ia2da3qsGMD-lmlF4pQe8b8FyM2E14J3VnZKh9eoIeDOagHgH01rllbtHN5IH3MO5LtDXy2q_fIs2H6_r5fMmMjFhPiolB8HqNC14mfM4yZosh5gVaVak0LCGCUrDrYSSk5URKeqcU6B1XaS1YCxZoKd_rrH6ZwTnq4Me7RBWVoEW55SxkobU4zk11j00lbGq53aqLs9L_gBXaG6G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352716691</pqid></control><display><type>article</type><title>Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gadakchi, Leyla ; Hajialilo, Mehrzad ; Nakhjavani, Mohammad-Reza ; Abedi Azar, Sima ; Kolahi, Sousan ; Gojazadeh, Morteza ; Ebrahimi, Ali-Asghar ; Malek Mahdavi, Aida ; Noshad, Hamid ; Khabbazi, Alireza</creator><creatorcontrib>Gadakchi, Leyla ; Hajialilo, Mehrzad ; Nakhjavani, Mohammad-Reza ; Abedi Azar, Sima ; Kolahi, Sousan ; Gojazadeh, Morteza ; Ebrahimi, Ali-Asghar ; Malek Mahdavi, Aida ; Noshad, Hamid ; Khabbazi, Alireza</creatorcontrib><description>Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that can lead to end-stage renal disease and death. The aim of this study was to compare the efficacy and safety of mycophenolate mofetil (MMF) and cyclophosphamide as induction therapy and subsequently as maintenance therapy for lupus nephritis.
In this retrospective case-control study, 67 patients with proliferative lupus nephritis who were treated with MMF (n = 45) and pulse of intravenous cyclophosphamide (n = 22) were included. Remission of the kidney disease, mortality, and adverse events were evaluated and compared between the two groups.
The 45 patients treated with MMF had a mean age of 33.8 ± 10.6 years and 17.1% of them were males. The 22 patients treated with pulse of intravenous cyclophosphamide had a mean age of 38.1 ± 11.1 years and 18.2% of them were males. Complete and partial kidney remission occurred in 40% and 42.2% of the patients treated with MMF and in 31.8% and 59.1% of the patients treated with cyclophosphamide, respectively. No significant differences were observed in complete and partial remission between the two groups. No mortality was reported in the studied patients. There were no significant differences in the frequency of adverse events between the two groups.
The efficacy of MMF in long-term treatment of lupus nephritis was comparable to that of cyclophosphamide, and there is no significant differences in the rate of side effects between the two regimens.</description><identifier>ISSN: 1735-8582</identifier><identifier>EISSN: 1735-8604</identifier><identifier>PMID: 30367020</identifier><language>eng</language><publisher>Iran: Iranian Society of Nephrology</publisher><subject>Administration, Intravenous ; Adult ; Case-Control Studies ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Female ; Health risk assessment ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Lupus ; Lupus Nephritis - drug therapy ; Male ; Mortality ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - adverse effects ; Remission Induction ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Young Adult</subject><ispartof>Iranian journal of kidney diseases, 2018-09, Vol.12 (5), p.288</ispartof><rights>Copyright Iranian Society of Nephrology 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30367020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gadakchi, Leyla</creatorcontrib><creatorcontrib>Hajialilo, Mehrzad</creatorcontrib><creatorcontrib>Nakhjavani, Mohammad-Reza</creatorcontrib><creatorcontrib>Abedi Azar, Sima</creatorcontrib><creatorcontrib>Kolahi, Sousan</creatorcontrib><creatorcontrib>Gojazadeh, Morteza</creatorcontrib><creatorcontrib>Ebrahimi, Ali-Asghar</creatorcontrib><creatorcontrib>Malek Mahdavi, Aida</creatorcontrib><creatorcontrib>Noshad, Hamid</creatorcontrib><creatorcontrib>Khabbazi, Alireza</creatorcontrib><title>Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis</title><title>Iranian journal of kidney diseases</title><addtitle>Iran J Kidney Dis</addtitle><description>Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that can lead to end-stage renal disease and death. The aim of this study was to compare the efficacy and safety of mycophenolate mofetil (MMF) and cyclophosphamide as induction therapy and subsequently as maintenance therapy for lupus nephritis.
In this retrospective case-control study, 67 patients with proliferative lupus nephritis who were treated with MMF (n = 45) and pulse of intravenous cyclophosphamide (n = 22) were included. Remission of the kidney disease, mortality, and adverse events were evaluated and compared between the two groups.
The 45 patients treated with MMF had a mean age of 33.8 ± 10.6 years and 17.1% of them were males. The 22 patients treated with pulse of intravenous cyclophosphamide had a mean age of 38.1 ± 11.1 years and 18.2% of them were males. Complete and partial kidney remission occurred in 40% and 42.2% of the patients treated with MMF and in 31.8% and 59.1% of the patients treated with cyclophosphamide, respectively. No significant differences were observed in complete and partial remission between the two groups. No mortality was reported in the studied patients. There were no significant differences in the frequency of adverse events between the two groups.
The efficacy of MMF in long-term treatment of lupus nephritis was comparable to that of cyclophosphamide, and there is no significant differences in the rate of side effects between the two regimens.</description><subject>Administration, Intravenous</subject><subject>Adult</subject><subject>Case-Control Studies</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Lupus</subject><subject>Lupus Nephritis - drug therapy</subject><subject>Male</subject><subject>Mortality</subject><subject>Mycophenolic Acid - administration & dosage</subject><subject>Mycophenolic Acid - adverse effects</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1735-8582</issn><issn>1735-8604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo1kN9KwzAUxoMobk5fQQJeF5L-SdtLGVMHmw6c3pY0PaEZbROTdNB38KHNcLs63znfx-9wzhWa0zzJooKR9PqisyKeoTvnDoSwpEzJLZolJGE5ickc_a6kVIKLCfOhwZ9cgp-wlng7CW1aGHTHPeCtDnPV4W-wbnR4PXjLj8EMejd2DvByEl3Ia2da3qsGMD-lmlF4pQe8b8FyM2E14J3VnZKh9eoIeDOagHgH01rllbtHN5IH3MO5LtDXy2q_fIs2H6_r5fMmMjFhPiolB8HqNC14mfM4yZosh5gVaVak0LCGCUrDrYSSk5URKeqcU6B1XaS1YCxZoKd_rrH6ZwTnq4Me7RBWVoEW55SxkobU4zk11j00lbGq53aqLs9L_gBXaG6G</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Gadakchi, Leyla</creator><creator>Hajialilo, Mehrzad</creator><creator>Nakhjavani, Mohammad-Reza</creator><creator>Abedi Azar, Sima</creator><creator>Kolahi, Sousan</creator><creator>Gojazadeh, Morteza</creator><creator>Ebrahimi, Ali-Asghar</creator><creator>Malek Mahdavi, Aida</creator><creator>Noshad, Hamid</creator><creator>Khabbazi, Alireza</creator><general>Iranian Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180901</creationdate><title>Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis</title><author>Gadakchi, Leyla ; Hajialilo, Mehrzad ; Nakhjavani, Mohammad-Reza ; Abedi Azar, Sima ; Kolahi, Sousan ; Gojazadeh, Morteza ; Ebrahimi, Ali-Asghar ; Malek Mahdavi, Aida ; Noshad, Hamid ; Khabbazi, Alireza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p206t-9faec6b448a97a235d57e2684584ed6d6c1100601035d550fcb7a1e1bb84bc663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Intravenous</topic><topic>Adult</topic><topic>Case-Control Studies</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Lupus</topic><topic>Lupus Nephritis - drug therapy</topic><topic>Male</topic><topic>Mortality</topic><topic>Mycophenolic Acid - administration & dosage</topic><topic>Mycophenolic Acid - adverse effects</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gadakchi, Leyla</creatorcontrib><creatorcontrib>Hajialilo, Mehrzad</creatorcontrib><creatorcontrib>Nakhjavani, Mohammad-Reza</creatorcontrib><creatorcontrib>Abedi Azar, Sima</creatorcontrib><creatorcontrib>Kolahi, Sousan</creatorcontrib><creatorcontrib>Gojazadeh, Morteza</creatorcontrib><creatorcontrib>Ebrahimi, Ali-Asghar</creatorcontrib><creatorcontrib>Malek Mahdavi, Aida</creatorcontrib><creatorcontrib>Noshad, Hamid</creatorcontrib><creatorcontrib>Khabbazi, Alireza</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Iranian journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gadakchi, Leyla</au><au>Hajialilo, Mehrzad</au><au>Nakhjavani, Mohammad-Reza</au><au>Abedi Azar, Sima</au><au>Kolahi, Sousan</au><au>Gojazadeh, Morteza</au><au>Ebrahimi, Ali-Asghar</au><au>Malek Mahdavi, Aida</au><au>Noshad, Hamid</au><au>Khabbazi, Alireza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis</atitle><jtitle>Iranian journal of kidney diseases</jtitle><addtitle>Iran J Kidney Dis</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>12</volume><issue>5</issue><spage>288</spage><pages>288-</pages><issn>1735-8582</issn><eissn>1735-8604</eissn><abstract>Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that can lead to end-stage renal disease and death. The aim of this study was to compare the efficacy and safety of mycophenolate mofetil (MMF) and cyclophosphamide as induction therapy and subsequently as maintenance therapy for lupus nephritis.
In this retrospective case-control study, 67 patients with proliferative lupus nephritis who were treated with MMF (n = 45) and pulse of intravenous cyclophosphamide (n = 22) were included. Remission of the kidney disease, mortality, and adverse events were evaluated and compared between the two groups.
The 45 patients treated with MMF had a mean age of 33.8 ± 10.6 years and 17.1% of them were males. The 22 patients treated with pulse of intravenous cyclophosphamide had a mean age of 38.1 ± 11.1 years and 18.2% of them were males. Complete and partial kidney remission occurred in 40% and 42.2% of the patients treated with MMF and in 31.8% and 59.1% of the patients treated with cyclophosphamide, respectively. No significant differences were observed in complete and partial remission between the two groups. No mortality was reported in the studied patients. There were no significant differences in the frequency of adverse events between the two groups.
The efficacy of MMF in long-term treatment of lupus nephritis was comparable to that of cyclophosphamide, and there is no significant differences in the rate of side effects between the two regimens.</abstract><cop>Iran</cop><pub>Iranian Society of Nephrology</pub><pmid>30367020</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1735-8582 |
| ispartof | Iranian journal of kidney diseases, 2018-09, Vol.12 (5), p.288 |
| issn | 1735-8582 1735-8604 |
| language | eng |
| recordid | cdi_proquest_journals_2352716691 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Intravenous Adult Case-Control Studies Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Female Health risk assessment Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Lupus Lupus Nephritis - drug therapy Male Mortality Mycophenolic Acid - administration & dosage Mycophenolic Acid - adverse effects Remission Induction Retrospective Studies Severity of Illness Index Treatment Outcome Young Adult |
| title | Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T09%3A17%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Mycophenolate%20Mofetil%20Versus%20Intravenous%20Pulse%20Cyclophosphamide%20as%20Induction%20Therapy%20in%20Proliferative%20Lupus%20Nephritis&rft.jtitle=Iranian%20journal%20of%20kidney%20diseases&rft.au=Gadakchi,%20Leyla&rft.date=2018-09-01&rft.volume=12&rft.issue=5&rft.spage=288&rft.pages=288-&rft.issn=1735-8582&rft.eissn=1735-8604&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2352716691%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352716691&rft_id=info:pmid/30367020&rfr_iscdi=true |